Literature DB >> 1831626

Ciclopirox nail lacquer 8%: in vivo penetration into and through nails and in vitro effect on pig skin.

C G Ceschin-Roques1, H Hänel, S M Pruja-Bougaret, J Luc, J Vandermander, G Michel.   

Abstract

This report presents original methods to assess the bioavailability of an antifungal drug from a varnish preparation in finger nails. For the studies with human volunteers a ciclopirox 8% nail lacquer was used to determine its efficacy in the treatment of onychomycoses. In vivo studies were performed on the fingernails of healthy volunteers by determining the total amount of ciclopirox penetrated per milligram of nail and the partition of the drug in the plate of the nails (technically divided into four layers). Ciclopirox concentrations were evaluated by measuring the inhibition of Candida pseudotropicalis growth in vitro. The ciclopirox concentration after 30 days treatment was determined as 3.35 +/- 0.82 micrograms/mg nail material. This is a sufficient amount to kill the fungal pathogens. In addition, in vitro penetration experiments were carried out with excised pig skin. Lacquer formulations from 0.5 to 8% were used to inhibit the growth of Trichophyton mentagrophytes. Formulations from 2 to 8% led to a strong to total inhibition of the dermatophyte after 30 min treatment time.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1831626     DOI: 10.1159/000210929

Source DB:  PubMed          Journal:  Skin Pharmacol        ISSN: 1011-0283


  7 in total

1.  A method to measure the amount of drug penetrated across the nail plate.

Authors:  J H Kim; C H Lee; H K Choi
Journal:  Pharm Res       Date:  2001-10       Impact factor: 4.200

Review 2.  An overview of topical antifungal therapy in dermatomycoses. A North American perspective.

Authors:  A K Gupta; T R Einarson; R C Summerbell; N H Shear
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

3.  Activity of TDT 067 (terbinafine in Transfersome) against agents of onychomycosis, as determined by minimum inhibitory and fungicidal concentrations.

Authors:  Mahmoud Ghannoum; Nancy Isham; Jacqueline Herbert; William Henry; Sam Yurdakul
Journal:  J Clin Microbiol       Date:  2011-03-16       Impact factor: 5.948

4.  Use of caryophyllene oxide as an antifungal agent in an in vitro experimental model of onychomycosis.

Authors:  D Yang; L Michel; J P Chaumont; J Millet-Clerc
Journal:  Mycopathologia       Date:  1999-11       Impact factor: 2.574

Review 5.  Treatment and prophylaxis of tinea infections.

Authors:  G E Piérard; J E Arrese; C Piérard-Franchimont
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

6.  [Modern antimycotics. What the treating physician needs to know].

Authors:  C Seebacher
Journal:  Hautarzt       Date:  2004-02       Impact factor: 0.751

7.  Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma.

Authors:  Baisheng Yuan; Wei Ji; Haipeng Xia; Jianmin Li
Journal:  Mol Med Rep       Date:  2018-01-10       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.